Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
09/20/17Natera Selected for Circulating Tumor DNA Study in Bladder Cancer
Denmark's Aarhus University to Use Signatera™ ctDNA Technology in Longitudinal Study SAN CARLOS, Calif., Sept. 20, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, has entered into a research collaboration with Denmark's Aarhus University to leverage the company's Signatera™ (RUO) personalized liquid biopsy technology to evaluate circulating tumor DNA (ctDNA) as a useful biomarker in the diagnosis and treatment of bladder cancer. Signatera™ was re... 
08/21/17Natera Launches Signatera™ Personalized Circulating Tumor DNA Technology for Cancer Research
SAN CARLOS, Calif., Aug. 21, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the launch of SignateraTM, a circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific to an individual's tumor, for research use only (RUO) by oncology researchers and biopharmaceutical companies. Already in clinical validation with multiple world-leading cancer institutes, SignateraTM offers a no... 
08/08/17Natera Reports Second Quarter 2017 Financial Results
SAN CARLOS, Calif., Aug. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2017 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $53.6 million in the second quarter of 2017 compared to $52.0 million in the second quarter of ... 
08/01/17Natera Inc. Announces Second Quarter 2017 Earnings Conference Call
SAN CARLOS, Calif., Aug. 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its second quarter ended June 30, 2017 after the market close on August 8, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: Event:             ... 
07/31/17Large Study Shows Natera’s Panorama Prenatal Screen To Be Highly Accurate in Identifying DNA Microdeletions Associated with Serious Health Implications
Study evaluated screening performance for 22q11.2, 1p36, Prader-Willi, Angelman, and cri-du-chat microdeletion syndromes Using new testing methodology, positive predictive values improved to 44.2% for 22q11.2 deletion syndrome and 31.7% for four other microdeletion disorders False positive rates decreased to 0.07% for 22q11.2 and 0.07% for the other four disorders combined Prevalence in... 
05/09/17Natera Reports First Quarter 2017 Financial Results
SAN CARLOS, Calif., May 9, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2017 and provided an update on recent business progress. Recent Accomplishments & Highlights Processed greater than 121,000 tests, including greater than 114,000 tests accessioned in Natera's laboratory and greater than 6,300 units processed through i... 
05/08/17Natera, Inc. Announces Launch of Vistara Single-Gene Mutation NIPT
A NIPT to screen for single gene disorders using cfDNA SAN CARLOS, Calif., May 8, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in genetic testing, announced the launch of Vistara, a non-invasive prenatal test (NIPT) to screen single-gene disorders. Vistara is a complement to Natera's market-leading Panorama® non-invasive prenatal test (NIPT) and screens for new mutations in 30 genes that have a combined incidence rate of nearly 1 in 600, which is higher than that of Down syndrome.1,... 
05/04/17Natera Announces the Appointment of Gail Marcus as Member of the Board of Directors
Experienced Healthcare Executive Adds Deep Experience in Managed Care and Market Access SAN CARLOS, Calif., May 4, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Gail Marcus as member of the board of directors, effective March 2017. Ms. Marcus has served as a consultant and practice leader in the healthcare consulting practice of Exceptional Leaders International since 2015.... 
05/02/17Natera Inc. Announces First Quarter 2017 Earnings Conference Call
SAN CARLOS, Calif., May 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its first quarter ended March 31, 2017 after the market close on May 9, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook.   Conference Call Information: Event:               N... 
04/26/17Study in Nature Shows Early Relapse Detection in Lung Cancer Using Natera's Technology for ctDNA Analysis
Relapse detected up to 347 days earlier than standard of care, with sensitivity and specificity exceeding 90% SAN CARLOS, Calif. and LONDON, April 26, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, and Cancer Research UK, University College of London (UCL) Cancer Institute and the Francis Crick Institute today announced the publication of results from the first 100 patients in the Cancer Research UK-funded TRACERx study (Tracking Cancer Evolutio... 
03/07/17Natera Reports Fourth Quarter and Fiscal Year 2016 Financial Results
SAN CARLOS, Calif., March 7, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $49.3 million in the fourth quarter of 2016 compared to $52.9 million... 
03/01/17Natera, Inc. Announces Launch of Evercord™ Cord Blood and Tissue Banking Service
Launch Expands Natera's Leadership Position in Women's Reproductive Health SAN CARLOS, Calif., March 1, 2017 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in genetic testing, today announced the upcoming launch of Evercord; a new offering being made commercially available in the second quarter of 2017 that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. ... 
02/28/17Natera Inc. Announces Fourth Quarter and Fiscal Year 2016 Earnings Conference Call
SAN CARLOS, Calif., Feb. 28, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2016 after the market close on March 7, 2017. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Confe... 
02/03/17Natera Inc. Announces Appointment of Mike Brophy as New Chief Financial Officer
Former Chief Financial Officer Herm Rosenman to Join Natera's Board of Directors SAN CARLOS, Calif., Feb. 3, 2017 /PRNewswire/ -- Natera Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced today the appointment of Mike Brophy as Natera's new chief financial officer, effective February 1, 2017. Mr. Brophy replaces Herman ("Herm") Rosenman, who joined the Company's board of directors effective February 1, 2017 following his three-year tenure as Natera's current CFO, a pos... 
01/17/17Natera Announces Results From DNAFirst Study, Validating Use Of NIPT In Routine Prenatal Care
Results demonstrate clinical utility of NIPT as first line screen in a general population Study results published in Genetics in Medicine SAN CARLOS, Calif., Jan. 17, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the results from the DNAFirst trial, showing that non-invasive prenatal screening tests (NIPT) can be effectively and appropriately offered as a primary screen for all pregnant women, regardless of risk due to matern... 
01/10/17Natera Inc. Terminates NIPT Distribution Agreement with Bioreference Labs
SAN CARLOS, Calif., Jan. 10, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, announced the termination of a distribution agreement with Bioreference Laboratories. With the ending of the distribution agreement, Natera intends to promote Panorama directly to clinicians, who previously ordered this test through Bio-Reference. Natera also plans to promote its Horizon carrier screen test to these clinicians, which it had not done previously. ... 
12/21/16Natera Provides Constellation™ Update
Cloud-based software platform continues to fuel growth and expansion into international markets SAN CARLOS, Calif., Dec. 21, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced the availability of a microdeletions testing application for new and existing Constellation licensees worldwide. With the addition of the microdeletions testing capability, Constellation is rapidly becoming a popular delivery platform to access Natera's innovat... 
12/14/16Natera Announces Participation In I-SPY 2 TRIAL For Breast Cancer
Natera to evaluate the effectiveness of liquid biopsy in monitoring breast cancer SAN CARLOS, Calif., Dec. 14, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a collaboration with Dr. Laura van 't Veer  and Dr. Laura Esserman of UCSF and QuantumLeap Healthcare Collaborative to participate in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Im... 
12/01/16The Centers For Medicare And Medicaid Services Establishes 2017 Pricing For Aneuploidy And Microdeletion Testing
SAN CARLOS, Calif., Dec. 1, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA announced today that the Centers for Medicare & Medicaid Services (CMS) released final determinations for the 2017 Clinical Lab Fee Schedule (CLFS), which included determinations for both aneuploidy and microdeletion testing described by Current Procedure Terminology (CPT) codes. CMS decided to cross-walk the aneuploidy (81420) and mic... 
11/22/16Natera to Present at the 28th Annual Piper Jaffray Health Conference
SAN CARLOS, Calif., Nov. 22, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 28th Annual Piper Jaffray Health Conference in New York on Tuesday, November 29, 2016 at 4:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the presentatio... 
11/09/16Natera Reports Third Quarter 2016 Financial Results
SAN CARLOS, Calif., Nov. 9, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $53.9 million in the third quarter of 2016 compared to $44.9 million in the third quarter of 2015, an increase of 20% Acces... 
11/02/16Natera Inc. Announces Third Quarter Earnings Conference Call
SAN CARLOS, Calif., Nov. 2, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 2016 after the market close on November 9, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: ... 
10/13/16Natera Announces Two Poster Presentations on Triploidy and Duchenne Muscular Dystrophy to be Featured at the 2016 American Society for Reproductive Medicine (ASRM) Conference
SAN CARLOS, Calif., Oct. 13, 2016 /PRNewswire/ --Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present data from Horizon™ carrier screen and Spectrum® pre-implementation genetic screening (PGS) studies at the Annual Meeting of the American Society for Reproductive Medicine (ASRM) Conference in Salt Lake City on Oct. 15-19, 2016. The diverse set of data that will be presented at the conference includes a... 
09/02/16Natera to Present at the Baird 2016 Global Healthcare Conference
SAN CARLOS, Calif., Sept. 2, 2016 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the Baird 2016 Global Healthcare Conference in New York, NY on Thursday, September 8, 2016 at 7:55 a.m. ET. Steve Chapman, Chief Commercial Officer of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the... 
08/04/16Natera Reports Second Quarter 2016 Financial Results
SAN CARLOS, Calif., Aug. 4, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $52.0 million in the second quarter of 2016 compared to $45.1 million in the second quarter of 2015, an increase of 15% Accessio... 
08/01/16Natera and UCSF Initiate Collaboration to Study DNA Markers of Kidney Transplant Rejection
SAN CARLOS, Calif., Aug. 1, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced a research collaboration with the University of California, San Francisco (UCSF), a leader in renal transplantation medicine in North America, to study the level of donor-derived cell-free DNA (dd-cfDNA) in over several hundred retrospectively banked plasma samples from kidney transplant recipients with and without organ ... 
07/29/16Statement from the American College of Medical Genetics and Genomics Supports the Use of Non-Invasive Prenatal Testing for All Pregnant Women
Natera, Inc. Praises New Practice Guidelines that Advocate NIPT screening for All Women, Regardless of Maternal Age SAN CARLOS, Calif., July 29, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, applauds the new guidelines just released by the American College of Medical Genetics and Genomics (ACMG), supporting the use of non-invasive prenatal tests (NIPT/NIPS) as an optimal, initial ... 
07/28/16Natera Announces Second Quarter Earnings Conference Call
SAN CARLOS, Calif., July 28, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, 2016 after the market close on August 4, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information ... 
07/18/16Unilabs Selects Natera, Inc.'s Panorama® Non-Invasive Prenatal Test (NIPT), Further Expanding Natera's Global Constellation™ Technology Transfer Business
SAN CARLOS, Calif., July 18, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA),a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, and Swiss-based Unilabs, one of Europe's leading providers of clinical laboratory testing and medical diagnostic imaging services, today announced a Constellation™ technology transfer licensing agreement that enables Unilabs to offer Panorama®, Natera's non-invasive prenatal test (NIPT).  Constellation allows laboratories worldwide ... 
06/30/16Natera Announces that the U.S. Supreme Court Denies Petition to Review '540 Patent Invalidation
SAN CARLOS, Calif., June 30, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced that the U.S. Supreme Court declined to review the Federal Circuit's determination that U.S. Patent 6,258,540 is invalid. The patent had broadly claimed the use of cell-free fetal DNA for genetic testing. Natera filed briefs supporting the Federal Circuit's determination and opposing Supreme Court review. "We are pleased wit... 
06/29/16Natera and Illumina Extend Supply Agreement, Broaden Existing Partnership to Include Oncology Field
SAN CARLOS, Calif., June 29, 2016 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced the extension of its supply agreement with Illumina, Inc., for up to 10 years. The agreement states that Illumina will supply Natera with sequencing systems and associated consumables for applications including non-invasive prenatal testing, transplant biology and for Natera's oncology diagnostic tests currently in develo... 
05/10/16Natera Reports First Quarter 2016 Financial Results
SAN CARLOS, Calif., May 10, 2016 /PRNewswire/ -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2016 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $61.9 million in the first quarter of 2016 compared to $47.4 million in the first quarter of 2015, an increase of 31% Accessio... 
05/03/16Natera Announces First Quarter Earnings Conference Call
SAN CARLOS, Calif., May 3, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its first quarter ended March 31, 2016 after the market close on May 10, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information: Ev... 
04/25/16Natera Announces the Appointment of Kimberly Martin, MD as Senior Global Medical Director, Women's Health Franchise
SAN CARLOS, Calif., April 25, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced today that Kimberly Martin, MD, FRCSC, FCCMG, FACOG, FACMG has assumed a new role as the new senior global medical director of Natera's Women's Health franchise. She previously served as the medical director for Reproductive Testing at Natera. Dr. Martin is a nationally recognized expert clinician in the field of ... 
03/11/16American Medical Association Grants New CPT Code for Microdeletion Testing
SAN CARLOS, Calif., March 11, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced the American Medical Association (AMA) has approved Natera's application for a Current Procedural Terminology, or CPT, code for fetal chromosomal microdeletion detection in circulating cell-free fetal DNA in maternal blood.  This code will be effective January 1, 2017. Natera submitted an application for this co... 
03/08/16Natera Reports Fourth Quarter and Fiscal Year 2015 Financial Results
SAN CARLOS, Calif., March 8, 2016 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the fourth quarter and fiscal year ended December 31, 2015 and provided an update on recent business progress. Recent Accomplishments & Highlights Generated total revenues of $52.9 million in the fourth quarter of 2015 compared to $49.9 million in the fourth quarter of 2014, an incre... 
03/07/16Published Study Demonstrates Natera's Ability to Identify Heterogeneous Cancer Mutations in Patients with Early-Stage Lung Cancer
Analysis of liquid biopsies can detect mutations that may be missed in tumor tissue biopsies SAN CARLOS, Calif., March 7, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in Annals of Oncology showing that Natera's massively multiplexed PCR (mmPCR) technology, coupled with its proprietary algorithms, can detect both ubiquitous (clonal) and heterogeneous (subclonal) tum... 
03/03/16Natera to Present at the Cowen and Company 36th Annual Health Care Conference
SAN CARLOS, Calif., March 3, 2016 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Wednesday, March 9, 2016 at 9:20 a.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the ... 
03/02/16Natera to Release Fourth Quarter and Fiscal Year 2015 Financial Results
SAN CARLOS, Calif., March 2, 2016 /PRNewswire/ - Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2015 after the market close on March 8, 2016. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Conference Call Information ... 
02/09/16Genetica Now Offering PanoramaTM NIPT in Switzerland via Natera's Constellation™ Software Platform
SAN CARLOS, Calif., Feb. 9, 2016 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Genetica, a leading laboratory for prenatal diagnostics in Switzerland, is now performing the Panorama non-invasive prenatal test (NIPT) at its genetics laboratory in Switzerland. Genetica is leveraging Natera's proprietary technology via Constellation, Natera's cloud-based software platform for clinical genomic analys... 
01/12/16Large-Scale Clinical Study Shows Panorama® Prenatal Screen to be Highly Accurate in Identifying 22q11.2 Deletion Syndrome in a General Population
Clinical evidence supports screening for 22q.11.2 in the general population SAN CARLOS, Calif., Jan. 12, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and analysis of circulating cell-free DNA, today announced the publication of the first major clinical-experience study, which covers the first six months of experience screening for 22q11.2 microdeletion syndrome using the Panorama non-invasive prenatal test (NIPT). The study by Gross, et al. pub... 
12/18/15MedGenome Now Offering Panorama™ NIPT in India via Natera's Constellation™ Cloud-based Software Platform
SAN CARLOS, Calif., Dec. 18, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that MedGenome, a leader in clinical genomic testing and a provider of genomic solutions for personalized healthcare in India, is now performing the Panorama non-invasive prenatal test (NIPT) at its genetics laboratory in Bangalore, leveraging Natera's proprietary technology and Constellation, Natera's cloud-based ... 
12/04/15Natera Announces the Appointment of Michael C. Little as Senior Vice President, R&D
SAN CARLOS, Calif., Dec. 4, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Michael C. Little, Ph.D. has joined the company as Senior Vice President, Research and Development. Prior to Natera, Dr. Little was the Global Head of Diagnostics Development at Novartis. During his tenure, Dr. Little managed the diagnostic development of all molecular diagnostic programs, as well as oncology a... 
11/24/15Natera to Present at the 27th Annual Piper Jaffray Health Conference
SAN CARLOS, Calif., Nov. 24, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the 27th Annual Piper Jaffray Health Conference in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the pr... 
11/19/15Natera Announces the Appointment of Jimmy Lin as Chief Scientific Officer for Oncology
SAN CARLOS, Calif., Nov. 19, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that Jimmy Lin, MD, PhD, MHS has been appointed as Chief Scientific Officer for Oncology. Dr. Jimmy Cheng-Ho Lin joins Natera coming from a long history as a pioneer in cancer genomics. Most recently, he led the clinical genomics program at the National Cancer Institute at the National Institutes of Health. Previously, at ... 
11/12/15Natera Reports Third Quarter 2015 Financial Results
SAN CARLOS, Calif., Nov. 12,  2015 /PRNewswire/ -- Natera,  Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis  of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2015 and provided an update on recent business progress. Recent Accomplishments & Highlights Accessioned greater than 83,000 tests in the third quarter of 2015 compared to approximately 57,000 tests accessioned in the third quarter of 2014, a... 
11/03/15LifeLabs Now Offering Panorama™ NIPT in Canada via Natera's Constellation Software Platform
Constellation™ software provides access to Natera's innovative bioinformatics through the cloud SAN CARLOS, Calif., Nov. 3, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that LifeLabs Medical Laboratory Services ("LifeLabs"), a leading Canadian laboratory services provider, is now performing the Panorama non-invasive prenatal test (NIPT) at its genetics laboratory in Toronto, lever... 
10/30/15Natera to Release Third Quarter 2015 Results on November 12, 2015
SAN CARLOS, Calif., Oct. 30, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its third quarter ended September 30, 2015 after the market close on November 12, 2015. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Event:    Natera's... 
10/28/15Natera Study Demonstrates Performance of mmPCR Technology in Identifying Breast Cancer
mmPCR can accurately detect CNVs with approximately 5 times higher sensitivity than existing methods First published report demonstrating detection of subclonal mutations in plasma that may be missed in tumor tissue biopsies SAN CARLOS, Calif., Oct. 28, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a study published in the October 2015 issue of Translational Oncology showing that Natera's... 
10/16/15Natera to Present at ASRM Annual Meeting
SAN CARLOS, Calif., Oct. 16, 2015 /PRNewswire/ -- Natera, Inc., (NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of reproductive genetic tests and screens will be highlighted during three scientific sessions at the American Society of Reproductive Medicine (ASRM) annual meeting, to be held October 17 – 21 in Baltimore, MD.  Natera Presentations at ASRM Size Matters: SNP-based ... 
10/06/15Natera to Present at ASHG Annual Scientific Conference
SAN CARLOS, Calif., Oct. 6, 2015 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that clinical research associated with its suite of genetic testing products will be highlighted during three scientific sessions at the American Society of Human Genetics (ASHG) annual meeting, to be held October 6–10 in Baltimore. MD. Natera Presentations at ASHG Detection of SNVs and CNVs in Circulating... 
08/12/15Natera Reports Second Quarter 2015 Financial Results
SAN CARLOS, Calif., Aug. 12, 2015 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the second quarter ended June 30, 2015 and provided an update on recent business progress. Recent Accomplishments & Highlights Achieved Total Revenue of $45.1 million in the second quarter of 2015, an increase of 26% over the same period of the prior year. Accessioned roughly 69,00... 
08/10/15Recent Publication Supports the Cost Effectiveness of NIPT for All Pregnant Women, Regardless of Prior Risk
SAN CARLOS, Calif., Aug. 10, 2015 /PRNewswire/ -- Natera, Inc., (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced new data that supports the use of non-invasive prenatal testing (NIPT) as a first line screening for chromosomal aneuploidies and related conditions. Peter Benn, DSc., Professor of Genetics at the UCONN Health Center, initiated a comprehensive economic analysis of NIPT and alternative methods, one of the first... 
08/04/15Natera to Release Second Quarter 2015 Results on August 12, 2015
SAN CARLOS, Calif., Aug. 4, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will release results for its second quarter ended June 30, 2015 after the market close on August 12, 2015. Natera will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss its financial results, business activities and financial outlook. Event:    Natera's Second ... 
07/08/15Natera Selected for NHS-Funded TRACERx Study of Lung Cancer Heterogeneity Using Cell-Free Tumor DNA
-- Natera's proprietary mmPCR technology to provide high sensitivity for blood-based detection of elusive subclonal tumor variations -- SAN CARLOS, Calif., July 8, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced a research collaboration with University College London (UCL) Cancer Institute, where the Institute will use Natera's proprietary technology to detect variations in cell-free circulating tumor D... 
07/01/15Natera Announces Pricing of Initial Public Offering
SAN CARLOS, Calif., July 1, 2015 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) today announced the pricing of its upsized initial public offering of 10,000,000 shares of its common stock at a price to the public of $18.00 per share before underwriting discounts, commissions and estimated expenses. In addition, Natera has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover over-allotments, if any. The shares are expected to begin t... 
05/28/15First Confirmed Detection of a Complete Molar Pregnancy with Cell-Free DNA Test
Precancerous condition identified in first trimester with PanoramaTM prenatal screen SAN CARLOS, Calif., May 28, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced a study published in Ultrasound in Obstetrics & Gynecology demonstrating that the Panorama single-nucleotide polymorphism (SNP)-based non-invasive prenatal test (NIPT) can identify a complete molar pregnancy in the first trimester. A study based upon data collected in the UK... 
04/24/15Natera and LifeLabs Announce Agreement for Panorama™ Non-Invasive Prenatal Test (NIPT) in Canada
SAN CARLOS, Calif., April 24, 2015 /PRNewswire/ -- Natera, Inc., a global leader in non-invasive genetic testing, and LifeLabs Medical Laboratory Services ("LifeLabs") today announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology. Pregnant women and their healthcare professionals will receive faster information about their fetus using world-class technology delivered through a Canadian based laboratory. Today... 
04/15/15Study Published in the Journal Science Identifies the First Genetic Variant Directly Correlated to Mitotic-Origin Aneuploidy in Human Embryos
- Study analyzed over 20,000 unique embryos using Spectrum™ Preimplantation Genetic Screening from Natera - SAN CARLOS, Calif., April 15, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, announced the publication of a study in the current issue of Science, which describes the identification of a genetic variant that influences the likelihood of aneuploidy in preimplantation embryos. Variants of this gene may help explain why some women take long... 
04/06/15Natera, Inc., Non-Invasive Genetic Testing Leader, Secures $55 Million in Private Financing
SAN CARLOS, Calif., April 6, 2015 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced that it has raised approximately $55.5 million in funding led by Silicon Valley life sciences investment firm Sofinnova Ventures. This financing round also includes participation from Capital Research and Management, Franklin Templeton Investments, Jennison Associates, RA Capital Management, Healthcor Partners and OrbiMed Advisors."We are very pleased to have led Natera's lat... 
12/18/14Published Study Shows Panorama™ NIPT Is Validated To Screen For Microdeletion Syndromes At 9 Weeks Of Pregnancy
-- Study suggests that screening in general pregnant population should be considered -- SAN CARLOS, Calif., Dec. 18, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced the publication of its validation study showing that the Panorama™ non-invasive prenatal test (NIPT) is highly accurate in screening for the most common and severe microdeletion syndromes. These tiny missing pieces of DNA at the sub-chromosomal level can have serious health impl... 
11/13/14Panorama Prenatal Screening Test Proven To Identify Vanishing Twins And Triploidy
-- SNP-based NIPT method reduces false positives and fetal sex errors -- Nov. 13, 2014 /PRNewswire/ -- Natera, Inc., a leader in non-invasive genetic testing, today announced its study showing that the Panorama™ NIPT successfully identifies vanished twin, previously unrecognized twin, and triploid pregnancies. This study is available online and will be published in the January 2015 issue of American Journal of Obstetrics and Gynecology. This is the first peer-reviewed publicati... 
08/13/14Major Clinical Study Supports NIPT As First Line Screening Test For All Pregnant Women
Analysis of over 17,000 cases finds that clinical performance of PanoramaTM NIPT is consistent in high and low risk populations Natera, Inc., a leader in non-invasive genetic testing, today announced a study to be published in the November issue of American Journal of Obstetrics and Gynecology, which shows that Panorama™ NIPT performs consistently well in all pregnant women, regardless of their prior risk level. This is the largest ever published study of clinical outcomes with NIPT, followi... 
07/31/14Study Results Show That Panorama™ Non-Invasive Prenatal Test (NIPT) Performs Reliably In Pregnant Women Of All Risk Levels
Natera, Inc., a leader in non-invasive genetic testing, today announced a study published in the August issue of Obstetrics and Gynecology, which demonstrates that the Panorama non-invasive prenatal test (NIPT) performs consistently well in all pregnant women, regardless of their prior risk level. This is the first major published study of Panorama that provides compelling scientific evidence for testing in the general population.This study of more than 1,000 pregnant patients, half of whom were... 
07/11/14Natera Achieves CE Mark for Its Cloud-based Analytical Software to Support the Panorama™ Non-invasive Prenatal Test
Natera, Inc., a leader in non-invasive genetic testing, today announced its cloud-based analytical software has achieved Conformité Européenne (CE) marking. This registration provides a significant step for Natera to license and sell its software throughout the European Union to support laboratory partners who will run Panorama in their own laboratories as an in vitro diagnostic (IVD).“The CE Mark is a milestone that reflects the quality and reliability of Natera's technology”“The CE Mark is a m... 
07/07/14Natera Launches Carrier Screening under Horizon™ Brand in Partnership with Mount Sinai Genetic Testing Laboratory
Natera, Inc. and the Mount Sinai Genetic Testing Laboratory have entered into a partnership to offer an expanded Horizon™ genetic carrier screening test for prospective families. Genetic carrier screening is performed to determine whether an individual is a carrier for certain recessive genetic disorders, and is often used by families who are pregnant or trying to conceive. Natera will offer the Horizon test to its OBGYN customers as part of its growing women’s health business.“Our partnership w... 
06/16/14Natera Enters into Partnership with the Feinstein Institute for Medical Research to Advance Cancer Diagnostics Research
Natera, Inc., a leader in non-invasive genetic testing, and the Feinstein Institute for Medical Research today announced that they have entered into a research agreement to analyze cell-free circulating tumor DNA (ctDNA) for advanced detection, diagnosis and monitoring of cancer. Under the terms of the agreement, Natera will provide funding to the Feinstein Institute, which will contribute blood and tissue samples to Natera for the development of technology that can detect tiny fragments of tumo... 
05/12/14Natera and the International 22q11.2 Foundation Establish Exclusive Partnership to Promote Early Screening of the 22q11.2 Deletion
Natera, Inc. and the International 22q11.2 Foundation today announced that they have entered into an exclusive partnership to raise awareness about 22q11.2 deletion syndrome and the importance of early diagnosis. The partnership is designed to encourage scientific research, influence current medical practice and raise awareness among the medical community and general population. One of the most common human genetic disorders, 22q11.2 deletion syndrome (“22q”) occurs when a small piece of the 22n... 
04/24/14Natera Receives Conditional Approval from New York State Department of Health for Panorama™ NIPT with 22q11.2 Deletion Syndrome
Natera, Inc., a leading innovator in prenatal genetic testing, today announced that it has received a new conditional approval from the New York State Department of Health to offer its Panorama™ non-invasive prenatal test (NIPT) for aneuploidies and 22q11.2 deletion syndrome in all pregnant women.“This conditional approval marks another major milestone for Natera, and it reflects the strength of Natera’s validation methodology,” said Matthew Rabinowitz, Ph.D., chief executive officer of Natera. ... 
03/14/14Natera Announces Launch of Panorama™ Non-Invasive Prenatal Test in Portugal and Thailand
Natera, Inc., a leading innovator in prenatal genetic testing, today announced two new partnerships to launch its Panorama™ non-invasive prenatal screening test (NIPT) outside of the United States. The Joaquim Chaves Group will manage the distribution of Panorama in Portugal, and Bangkok Cytogenetics Center will manage its distribution in Thailand. “There is a strong demand for accurate and comprehensive prenatal screening tests outside of the U.S., and these two partnerships are an integra... 
02/12/14Natera Initiates Partnership with ProPath for Distribution of Panorama™ Non-Invasive Prenatal Test in United States
Natera, a leading innovator in prenatal genetic testing, today announced the initiation of a distribution partnership with ProPath, a wholly physician-owned provider of pathology services to clinicians and medical facilities in the United States, for its Panorama™ non-invasive prenatal screening test (NIPT).Panorama has been validated globally in multiple clinical trials and is the only NIPT to consistently demonstrate high sensitivity and specificity for all major aneuploidies beyond Down syndr... 
02/05/14Natera Expands Panorama™ Non-Invasive Prenatal Test to Screen for Clinically Significant Microdeletions
Screening for 22q11.2 Deletion to Become Standard Natera, a leading innovator in prenatal genetic testing, today announced the expansion of the Panorama™ non-invasive prenatal test (NIPT) to screen for five clinically relevant microdeletion syndromes. The expanded test will become available on March 1, 2014.Microdeletions are tiny missing pieces of DNA at the sub-chromosomal level, which can have serious health implications depending on the location of the deletion. Beginning on March 1, scr... 
01/31/14Natera Appoints Herm Rosenman as Chief Financial Officer
Natera Inc., a leading innovator in prenatal genetic testing, today announced the appointment of Herman “Herm” Rosenman to the position of chief financial officer. Mr. Rosenman brings more than 30 years of public company operating and financial experience to Natera. He will join the company on Feb. 10, 2014.Mr. Rosenman was most recently the senior vice president of finance and chief financial officer of Gen-Probe Inc., where he was instrumental in its September 2002 IPO and its August 2012 sale... 
12/23/13Natera Receives New York State Laboratory Permit for Its Portfolio of Next-Generation Preconception and Prenatal Genetic Tests
Approval Includes the Panorama™ Non-Invasive Prenatal Test, Preimplantation Genetic Diagnosis (PGD) and Non-Invasive Prenatal Paternity Testing Natera, a leading innovator in prenatal genetic testing, today announced that the New York State Department of Health has issued a clinical laboratory permit for the company’s CLIA-certified laboratory in San Carlos, Calif., enabling the company to make its portfolio of next-generation preconception and prenatal tests available to expecting parents i... 
12/20/13Natera Names Susan Gross, M.D., Chief Medical Officer
Natera, a leading innovator in prenatal genetic testing, today announced the addition of Susan Gross, M.D., as the company’s first chief medical officer. She brings to Natera more than 25 years of experience in the field of prenatal genetics. The addition of Dr. Gross reflects Natera’s focus on solidifying its technology leadership position and advancing a strong R&D pipeline for future innovation.Dr. Gross is a professor of clinical obstetrics & gynecology and women’s health, pediatrics... 
12/16/13DiagCor to Launch Natera’s Panorama™ Non-Invasive Prenatal Test in Hong Kong
Natera today announced that DiagCor, a manufacturer of in-vitro diagnostic products and service provider of clinical diagnostic tests, has signed an agreement to launch Natera’s Panorama™ non-invasive prenatal screening test (NIPT) in Hong Kong. Panorama uses a simple blood draw from the mother to detect trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner’s syndrome), triploidy (Triploid syndrome), and sex chromosome aneuploidies. The test, ... 
11/04/13Hospital Israelita Albert Einstein and Natera Partner to Offer Panorama™, Natera’s Non-Invasive Prenatal Test for Detection of Chromosomal Abnormalities
Leading South American Hospital to Provide Test with Ability to Detect Trisomy 21, 18 and 13, Monosomy X, Triploidy, Vanishing Twins and Gender at Nine Weeks Gestation Hospital Israelita Albert Einstein and Natera, a leading innovator in prenatal genetic testing, today announced a partnership to offer Panorama™, Natera’s non-invasive prenatal test. Panorama currently offers detection of chromosomal abnormalities, including trisomy 21 (Down syndrome), trisomy 13 (Patau Syndrome), triso... 
11/01/13Natera’s Non-Invasive Prenatal Test, Panorama™, to be Offered as Part of the California Prenatal Screening Program
Women with Positive Serum Screening Results Through the California Prenatal Screening Program Will Have Access to Panorama at No Cost Natera, a leading innovator in prenatal genetic testing, today announced that its non-invasive prenatal test (NIPT), PanoramaTM, will now be available to expecting parents in California at no cost as part of the California Prenatal Screening Program. Panorama was launched in March 2013 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards... 
10/29/13Natera and Médica Fértil Announce Birth of First Baby in Mexico to be Screened with Non-Invasive Prenatal Test, Panorama™
Oct. 29, 2013 – Natera, a leading innovator in prenatal genetic testing, and Médica Fértil today announced the birth of the first baby in Mexico whose mother was screened with PanoramaTM, Natera’s non-invasive prenatal test. Panorama was launched in March 2013 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome). Detection of triploidy was added to Panorama in October 2013."After many years of waiting, we are... 
10/15/13Natera Selected as a 2013 Fierce 15 Device and Diagnostic Company
Annual Award by FierceMedicalDevices Recognizes Most Promising Private Companies in Med Tech Space Natera, a leading innovator in prenatal genetic testing, today announced that it has been named by FierceMedicalDevices as a 2013 Fierce 15 device and diagnostic company, designating it as one of the most promising private companies in the med tech space. This is FierceMedicalDevices’ second annual Fierce 15 selection.In March 2013, Natera launched Panorama for the detection of trisomy 2... 
10/14/13Natera Expands Panorama™ to Include Detection of Triploidy, Following Publication of Validation Data in Fetal Diagnosis and Therapy
Natera Improves Turnaround Time to 7-10 Calendar Days Natera, a leading innovator in prenatal genetic testing, today announced that, following publication of validation data in Fetal Diagnosis and Therapy, its non-invasive prenatal test Panorama™ is being expanded to offer detection of triploidy. Natera launched Panorama in March 2013 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome). Additional... 
09/16/13Natera and Solstas Lab Partners Enter Distribution Agreement for Non-Invasive Prenatal Test, Panorama™
Solstas Lab Partners®, one of the nation's fastest-growing full-service laboratories, and Natera, a leading innovator in reproductive and prenatal genetic testing, today announced a distribution agreement that will make Natera’s non-invasive prenatal screening test, Panorama™, available to Solstas’ clients nationwide. Panorama was launched earlier this year for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnorm... 
09/11/13Natera Partners with LifeLabs Medical Laboratory Services to Distribute Non-Invasive Prenatal Test Panorama™ in Canada
Natera, a leading innovator in prenatal genetic testing, and LifeLabs Medical Laboratory Services (LifeLabs), a Canadian company with over 50 years’ experience in laboratory testing and management, today announced a distribution partnership for Natera’s non-invasive prenatal screening test, Panorama™. Panorama was launched in March 2013 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as mono... 
08/27/13World Economic Forum Selects Natera as 2014 Technology Pioneer
Company Recognized for Innovation in Prenatal Care, Including Development of Best-In-Class Non-Invasive Prenatal Tests Panorama™Only Molecular Diagnostic Company Among Those Selected for the Award Natera, a leading innovator in prenatal genetic testing, has been selected by the World Economic Forum as a 2014 Technology Pioneer. The recognition is based on Natera's innovation in prenatal care, including developing the non-invasive prenatal screening test, Panorama?, for the detection o... 
08/08/13DASA Group to Provide Natera’s Panorama™ Non-Invasive Prenatal Test for Detection of Chromosomal Abnormalities, Such as Down Syndrome, from the Ninth Week of Gestation
DASA Group and Natera today announced that DASA Group will begin offering Natera’s non-invasive prenatal test (NIPT) Panorama ™ for the detection of genetic syndromes common in the population, such as trisomy 21 (Down syndrome), trisomy 13 (Patau Syndrome ), trisomy 18 (Edwards syndrome) and monosomy X (Turner syndrome). The test uses a simple blood draw from the mother and can be performed within the first trimester of pregnancy, as early as nine weeks, without any risk to the fetus.According t... 
06/27/13Data Demonstrating Accurate Detection of Multiple Sex Chromosome Abnormalities by Natera’s Panorama™ NIPT Published in Prenatal Diagnosis
Natera, a leading innovator in prenatal genetic testing, announced today that data demonstrating the accuracy of its non-invasive prenatal screening test, Panorama™, in detection of multiple sex chromosome abnormalities were published in Prenatal Diagnosis.Data were obtained from an independent study of Panorama for detection of 45,X (monosomy X), 47,XXY and 47,XYY in 201 samples, 16 of which were afflicted with sex chromosome abnormalities. Panorama analyzed five chromosomes in each sample, wit... 
06/13/13Unilabs and Natera Initiate Partnership for Distribution of Non-Invasive Prenatal Test, Panorama™, in Switzerland/Scandinavia
Unilabs, a leading diagnostics company in Europe, and Natera, a leading innovator in prenatal genetic testing, announced today that Unilabs will distribute Natera’s non-invasive prenatal screening test, Panorama™, across its wide network in Switzerland and Scandinavia. Panorama was launched in March 2013 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turner’s syndrome).“Unila... 
05/15/13Natera and Echevarne Collaborate to Launch New Non-Invasive Prenatal Test Panorama™ in Spain, Iberia
Natera, a leading innovator in prenatal genetic testing, and Echevarne, a leading clinical analysis laboratory in Spain, today announced the signing of a distribution agreement for Echevarne to offer Natera’s non-invasive prenatal screening test (NIPT), Panorama™, through its facilities in Spain. Panorama was launched in March 2013 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy ... 
05/12/13amedes und Natera bieten gemeinsam nicht-invasiven Test für die Pränataldiagnostik in Deutschland an
Ab sofort wird die amedes Gruppe den Natera-Test für nicht-invasive Pränataldiagnostik in Deutschland vertreiben. amedes, bundesweit tätiger diagnostischer Dienstleister, teilte heute den Vertragsabschluss mit der US-amerikanischen Diagnostikfirma mit. Der Panorama TM – Test wird bereits in den USA und anderen europäischen Ländern angeboten.Panorama™ ist ein Bluttest, der mit einem innovativen molekulargenetischen Verfahren eine Risikoabschätzung für Chromosomenstörungen des ungeborenen Kindes e... 
05/01/13Natera Completes $54.6 Million Financing to Support Expansion, Continued Global Rollout of Non-Invasive Prenatal Test Panorama™
Financing Adds Leading Growth Stage Investors to Existing Syndicate Natera today announced that it has completed a $54.6 million financing round to support the expansion and continued global rollout of Natera’s non-invasive prenatal test, Panorama™. The financing round included two new lead investors, OrbiMed Advisors and Harmony Partners, as well as other undisclosed new investors. All existing investors participated, including Claremont Creek Ventures, Lightspeed Venture Partners, F... 
05/01/13Data Published in Prenatal Diagnosis Demonstrate Panorama’s Ability to Accurately Detect Chromosomal Abnormalities
Blinded, Independent Study Shows Proprietary Technology Accurately Detected Trisomy 21, Trisomy 13, Trisomy 18, Monosomy X and Triploidy The Fetal Medicine Foundation and Natera today announced the publication of data in Prenatal Diagnosis demonstrating the high accuracy of Natera’s non-invasive prenatal testing technology, which detected all cases of trisomy 21 (Down syndrome), trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), monosomy X (Turner’s syndrome) and triploidy us... 
03/18/13ARUP Laboratories Announces Availability of Natera's Non-Invasive Prenatal Test, Panorama™
ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory, and Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that Natera's non-invasive prenatal screening test, Panorama™, is available to ARUP clients nationwide.The test is available for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turner's syndrome)."... 
02/27/13Bio-Reference Laboratories, Inc. Will Offer Non-Invasive Prenatal Testing (NIPT) From Natera
Bio-Reference Laboratories, Inc. (BRLI) announced today that the Company and Natera have entered into a definitive agreement to commercialize the Panorama(TM) non-invasive prenatal screening test developed by Natera. The Panorama test will be sold by the GenPath business unit of Bioreference.Panorama is a simple blood test that uses cutting-edge genotyping and sequencing technologies to identify chromosomal aneuploidies such as trisomies 13, 18, 21, and certain sex-chromosome abnormalities. Acco... 
02/20/13Quest Diagnostics to Provide Nationwide Access to Natera’s New Non-Invasive Prenatal Test
Quest Diagnostics (NYSE:DGX), the world’s leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.Panorama uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and mo... 
02/20/13Natera Launches Non-Invasive Prenatal Test Panorama™ with Best-in-Class Sensitivity, Specificity for Detection of Fetal Chromosomal Abnormalities
Panorama’s clinical validation data was presented live at the annual Society of Maternal Fetal Medicine Meeting on February 15, 2013. Natera, a leading innovator in reproductive and prenatal genetic testing, today announced that the company’s non-invasive prenatal screening test, Panorama™, will launch on March 1 for the detection of trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and select sex chromosome abnormalities, such as monosomy X (Turne... 
02/13/13Validation Data Presented by Natera Demonstrates Best-in-Class Specificity and Sensitivity of Non-Invasive Prenatal Test Panorama™
Data Presented at Society for Maternal-Fetal Medicine Annual Meeting Natera today announced the presentation of validation data demonstrating unmatched specificity and sensitivity of the company's non-invasive prenatal test, Panorama(TM). The presentation, titled "Use of targeted sequencing of SNPs to achieve a highly accurate non-invasive detection of fetal aneuploidy of 13, 18, 21, and sex chromosomes," is being delivered at the annual meeting of the Society for Maternal-Fetal Medic... 
Shareholder Tools